VERTEX PHARMACEUTICALS INC

Vertex’s stock jumps 7% after a rival CF drug trial fails, underscoring its strong market position, high margins, and future growth prospects in cystic fibrosis therapy.

Vertex’s Q2 2026 earnings preview: deep dive into CF revenue trends, margin outlook, and next‑gen therapies that could shape the specialty pharma market.

Vertex expands R&D in oncology & immunology, partners on a $250 M biopharma deal, boosting its $3.7 B pipeline and long‑term growth outlook.

Vertex Pharmaceuticals’ July 10 share drop reflects a broader healthcare pullback amid tech‑driven growth; discover how regulatory, patent, and R&D dynamics shape its future.

Vertex expands beyond CF by acquiring Crinetics’ Lanreotide for acromegaly and partnering on a CF triple‑combination therapy—boosting revenue and deepening rare‑disease innovation.

Explore how Vertex’s cutting‑edge R&D, China’s new drug‑approval rules, and global integrated platforms could boost earnings—and what investors should watch next.

Vertex Pharmaceuticals’ shares hit a new 52‑week high, buoyed by breakthrough CF, gene‑editing, and KRAS trial data that boost investor confidence.

Vertex expands CASGEVY to kids as young as 2, giving new hope for sickle cell and beta‑thalassemia patients with a single‑dose cure‑potential therapy.

Vertex Pharmaceuticals’ recent Rule 144 filing shows a routine insider sale of 4,062 shares—no impact on its CF drug pipeline or market position.

Vertex’s early‑stage data for pediatric drug Casgevy shows 38 % biomarker drop and no serious AEs, hinting at a new growth avenue beyond cystic fibrosis.